Crossmark

Innovative Drug Development Approach to Address the Transition to Low Global Warming Potential Propellant Using Hydrofluoroalkane-152a, for Triple Combination Pressurized Metered-Dose Inhaler Products Targeting Small Airways

Crossref DOI link: https://doi.org/10.1208/s12249-025-03057-z

Published Online: 2025-02-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matturro, A. https://orcid.org/0009-0002-0502-3001
Zambelli, E.

Cuoghi, E.

Copelli, D.

Usberti, F.

Fioni, A.

Labadini, L.
License Information

Text and Data Mining valid from 2025-02-26

Version of Record valid from 2025-02-26
More Information

Article History

Received: 18 September 2024

Accepted: 27 January 2025

First Online: 26 February 2025

Change Date: 15 March 2025

Change Type: Update

Change Details: The original article has been updated to correct corresponding author's email address.

Declarations

:

: All the authors of the present article are employees of Chiesi Farmaceutici S.p.A.

Document is current

Any future updates will be listed below